Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santhera Shores Up Finances With Chiesi Deal for Raxone

Executive Summary

In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.

Advertisement

Related Content

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals
Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate
Santhera To Snap Up Second DMD Drug As Idorsia Climbs Aboard
Santhera Confident Of Raxone DMD Success Despite Setbacks
Santhera Expands Pipeline With Polyphor Cystic Fibrosis Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125279

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel